Form 8-K - Current report:
SEC Accession No. 0001140361-25-006524
Filing Date
2025-02-28
Accepted
2025-02-28 16:11:53
Documents
22
Period of Report
2025-02-24
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 1.02: Termination of a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.02: Unregistered Sales of Equity Securities
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ef20044715_8k.htm   iXBRL 8-K 51993
2 EXHIBIT 4.1 ef20044715_ex4-1.htm EX-4.1 891452
3 EXHIBIT 99.1 ef20044715_ex99-1.htm EX-99.1 12451
4 EXHIBIT 99.2 ef20044715_ex99-2.htm EX-99.2 14695
8 image00006.jpg GRAPHIC 2518
9 image00007.jpg GRAPHIC 2532
10 image00008.jpg GRAPHIC 2039
11 image00009.jpg GRAPHIC 2620
12 image00010.jpg GRAPHIC 2425
13 image00011.jpg GRAPHIC 3651
  Complete submission text file 0001140361-25-006524.txt   1298977

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA bbio-20250224.xsd EX-101.SCH 3985
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE bbio-20250224_lab.xml EX-101.LAB 21966
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE bbio-20250224_pre.xml EX-101.PRE 16046
24 EXTRACTED XBRL INSTANCE DOCUMENT ef20044715_8k_htm.xml XML 4225
Mailing Address 3160 PORTER DR. SUITE 250 PALO ALTO CA 94304
Business Address 3160 PORTER DR. SUITE 250 PALO ALTO CA 94304 (650) 391-9740
BridgeBio Pharma, Inc. (Filer) CIK: 0001743881 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38959 | Film No.: 25690299
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)